CIIC and Trio Health Introduce the Creation of a Dynamic Rare Disease Patient Registry Platform

Trio Health, in partnership with the Consortium of Independent Immunology Clinics, has launched the creation of a dynamic rare disease patient registry platform to transform drug development for allergy, asthma, and immunology patients.

Photo: Maeve O’Connor, president CIIC

This technology-driven and real-world data-based partnership will unite the power of the CIIC’s provider network with Trio’s proven data management technologies to create a comprehensive, real-world patient registry that bridges the gap within the industry today.

The real-world data platform will deliver customizable services to support the entire product lifecycle, including real-time drug surveillance, retrospective and prospective analysis of patient data, and accelerated identification of patients for clinical studies.

Trio is a leading provider of real-world data and insights with data management capabilities. Trio’s mission is to improve the quality of care and patient outcomes by coordinating the efforts of all patient care stakeholders. Their first-of-its-kind Multi-Disease Platform (MDX) tracks patients throughout the course of their treatment, and provides that information to biopharmaceutical companies, specialty pharmacies, and physicians.

CIIC is a professional medical organization represented by a group of board-certified allergists and immunologists in private practice throughout the United States who provide care for patients with primary immune deficiency disorders (PIDD), allergies, asthma, and other rare diseases requiring immune therapies.

“The CIIC’s new strategic partnership with Trio marks an exciting new chapter for the CIIC and our members,” said CIIC President Maeve O’Connor. “We see this as a milestone for us, as an organization and as physicians, to be a driving force in innovation and patient care breakthroughs in the asthma, allergy, and immunology clinical trials space. We anticipate that the patient and treatment insights to be gained from merging our CIIC members’ retrospective and prospective clinical data are going to be truly incredible. This partnership brings us one step closer to achieving the CIIC Organization’s mission of advocating for and providing cutting-edge therapy to our patients.”

Author: Rare Daily Staff